Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Rascol

Showing results (171-180 of 220) with videos related to

Pageof 22
Sort By:
Clinical Neuropharmacology|August 1, 1990
CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's diseaseO Rascol, N Fabre, H Teräväinen, et al.
Neurology|May 9, 2001
Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's diseaseS Descombes, A M Bonnet, U E Gasser, et al.
European Journal of Neurology|August 1, 2012
Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's diseaseA H V Schapira, P Barone, R A Hauser, et al.
European Journal of Neurology|April 28, 2012
Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's diseaseA H V Schapira, P Barone, R A Hauser, et al.
European Journal of Neurology|May 17, 2014
Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's diseaseR A Hauser, A H V Schapira, P Barone, et al.
Neurology|August 12, 2011
Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trialAnthony H V Schapira, P Barone, R A Hauser, et al.
Acta Neuropathologica|July 21, 1999
A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsyM B Delisle, J R Murrell, R Richardson, et al.
Clinical Neuropharmacology|June 9, 1998
The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's diseaseA E Schrag, D J Brooks, E Brunt, et al.
Neurology|August 12, 2011
Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trialW Poewe, O Rascol, P Barone, et al.
European Journal of Neurology|September 24, 2017
L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK surveyS Perez-Lloret, L Negre-Pages, P Damier, et al.
Pageof 22

Showing results (171-180 of 220) with videos related to

Sort By:
Pageof 22
Clinical Neuropharmacology|August 1, 1990
CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's diseaseO Rascol, N Fabre, H Teräväinen, et al.
Neurology|May 9, 2001
Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's diseaseS Descombes, A M Bonnet, U E Gasser, et al.
European Journal of Neurology|August 1, 2012
Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's diseaseA H V Schapira, P Barone, R A Hauser, et al.
European Journal of Neurology|April 28, 2012
Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's diseaseA H V Schapira, P Barone, R A Hauser, et al.
European Journal of Neurology|May 17, 2014
Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's diseaseR A Hauser, A H V Schapira, P Barone, et al.
Neurology|August 12, 2011
Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trialAnthony H V Schapira, P Barone, R A Hauser, et al.
Acta Neuropathologica|July 21, 1999
A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsyM B Delisle, J R Murrell, R Richardson, et al.
Clinical Neuropharmacology|June 9, 1998
The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's diseaseA E Schrag, D J Brooks, E Brunt, et al.
Neurology|August 12, 2011
Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trialW Poewe, O Rascol, P Barone, et al.
European Journal of Neurology|September 24, 2017
L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK surveyS Perez-Lloret, L Negre-Pages, P Damier, et al.
Pageof 22